The experimental drug bavdegalutamide showed the most pronounced effect in patients whose tumors had specific androgen receptor mutations. In nearly 60% of participants in this subgroup, prostate-specific antigen (PSA) levels fell by at least half. The results of the phase I/II trial were published in the Journal of Clinical Oncology.

One way to slow prostate cancer growth is to deprive the tumor of signals transmitted by testosterone and other androgens. Over time, cells can adapt to this treatment. Bavdegalutamide works differently: it targets the receptor itself for degradation through the system cells use to dispose of unwanted proteins.

The trial enrolled men with metastatic prostate cancer that had become resistant to therapy suppressing androgen activity. The most pronounced PSA changes were observed in patients with mutations at positions T878 and H875. In those with other genetic profiles, PSA reductions of at least half were much less common.

PSA is one of the markers doctors use to monitor a tumor's response to treatment. The difference between the groups suggests a way to select patients for future trials: look for tumors that are particularly sensitive to receptor degradation.

In the first part of the trial, researchers determined the dose, and in the second, they compared responses in patients with different receptor variants. In the subgroup with T878 and H875 mutations, the median time to progression on imaging or death was about 11 months. In participants with other genetic profiles, it was about four to five months. The comparison was between subgroups receiving the same drug.

The trial results suggest that certain receptor mutations may help identify patients whose tumors are more sensitive to bavdegalutamide. This gives researchers a basis for selecting patients for future trials of the drug.